<DOC>
	<DOCNO>NCT02306889</DOCNO>
	<brief_summary>The study conduct open label , balance , randomize , two-treatment , two-period , two-sequence , crossover bioequivalence study compare single oral dose fenofibrate capsule , USP 130 mg , Ohm Laboratories Inc. USA ( subsidiary Ranbaxy Pharmaceutical Inc. ) AntaraÂ® ( fenofibrate ) Capsules 130 mg Oscient Pharmaceuticals Corporation USA , healthy , adult , male , human subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Fenofibrate Capsules , 130 mg Under Fasting Conditions</brief_title>
	<detailed_description>The subject subject breath test alcohol test drug abuse ( opioids cannabinoids ) urine prior admission period . All subject fast overnight least 10 hour morning dose 4 hour post-dose period study . A single oral dose either test ( T ) reference ( R ) administer 240 mL drinking water ambient temperature supervision train study personnel . Both test reference product administer study subject , one period ( except subject number 17 , 27 42 ) . Blood sample collect Predose ( duplicate ) 1.000 , 2.000 , 2.500 , 3.000 , 3.500 , 4.000 , 4.500 , 5.000 , 5.500 , 6.000 , 6.500 , 7.000 , 7.500 , 8.000 , 8.500 , 9.000 , 10.000 , 11.000 , 12.000 , 16.000 , 24.000 , 36.000 , 48.000 , 72.000 96.000 hour post dose , pre-chilled vacutainers , low light condition , period complete subject . The pre-dose blood sample period collect duplicate ( 2 x 5 mL ) , within period 1.5 hour dosing . The actual end time collection blood sample record . During course study , safety parameter assess vital sign , clinical examination , medical history clinical laboratory safety test ( hematology , biochemical parameter , serology urine analysis screening ) . Adverse event monitoring do throughout study . Laboratory parameter hematology biochemistry repeat end study .</detailed_description>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Volunteers meet follow criterion include study Were age range 1845 year . Were neither overweight underweight his/her height per Life Insurance Corporation India height/weight chart nonmedical case Had voluntarily give write informed consent participate study . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . History hypersensitivity fenofibrate relate drug . Subjects history hepatic severe renal dysfunction , include primary biliary cirrhosis . Subjects history unexplained persistent liver function abnormality . Subject history myalgia , muscle tenderness weakness myopathy . History abdominal pain one week precede study . History recurrent headache and/or back pain . History constipation and/or nausea one week precede study . History and/or find gall bladder disease . History pancreatitis . History druginduced rash and/or pruritis . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . Subject laboratory test parameter ( ) , is/are outside acceptable limit judge clinically significant . Subject history serious medical illness include limited gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes , glaucoma , serious , potentially lifethreatening illness . Inability communicate well ( i.e . language problem , poor mental development , psychiatric illness poor cerebral function ) might impair ability provide , write informed consent . Subject regular smoker , smoke 10 cigarette daily difficulty abstain smoke duration study period . Subject history drug dependence excessive alcohol intake habitual basis difficulty abstain duration study period consume alcohol 48 hour prior admission . Subject use enzyme modify drug within 30 day prior admission study . Subject participate clinical trial within 12 week precede admission study ( except subject dropout / withdrawn previous study prior period 1 dosing ) Subject donate and/or lose 350 mL blood past 3 month , include blood loss study . Consumption alcohol 48 hour prior admission . Subject problem ( ) comply study protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>